



ITW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: BORRELLI =2A

In re Application of:)	Conf. No.: 8379
)	
Francesco BORRELLI et al)	Art Unit: 1614
)	
Appln. No.: 10/666,335)	Examiner:
)	
Filed: September 22, 2003)	Washington, D.C.
)	
For: TUMOR NECROSIS FACTOR)	May 26, 2005
ANTAGONISTS AND...)	
)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Randolph Building, Mail Stop Amendments
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[X] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.


[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:



Sheridan Neimark
Registration No. 20,520

:jaa

G:\BN\S\SER1\Borrelli2A\pto\IDS 26may05.doc
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528



Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of 2

Application Number	10/666,335
Filing Date	September 22, 2003
First Named Inventor	BORRELLI et al
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	BORELLI =2A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	BM	US-2004/0120952 A1	06-24-2004	KNIGHT et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	BN	WO 92/16553 A1	10-01-1992	NEW YORK UNIVERSITY; CENTOCOR, INC.		

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of 2

Complete if Known

Application Number	10/666,335
Filing Date	September 22, 2003
First Named Inventor	BORRELLI et al
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	BORRELLI=2A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BO	BALASCH, et al, "Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical study", Human Reproduction, 1997. 12(9):2046-2050..	
	BP	BARONE, et al, "Tumor Necrosis Factor- α : A mediator of Focal Ischemic Brain Injury", Stroke. June 1997. 28(6): 1233-1244.	
	BQ	BRAUN, Donald and Paul Dmowski, "Endometriosis: abnormal endometrium and dysfunctional immune response" Adult and Pediatric Gynecology. 1998. 10:365-369.	
	BR	GLEICHER, N. "Immune dysfunction - a potential target for treatment on endometriosis", British Journal of Obstetrics and Gynecology, October 1995, 102(suppl 12):4-7.	
	BS	HARADA, et al, "Role of cytokines in progression of endometriosis", Gynecologic and Obstetric Investigation. 1999. 47(suppl 1):34-40.	
	BT	JONES, Robert, "The effect of a luteinizing hormone-releasing hormone antagonist on experimental endometriosis in the rat" Acta Endocrinologica (Copenh). 1987. 114:379-382.	
	BU	Mims; "Open Up and breathe", Feb. 2004. Boehringer Ingelheim. p.147.	
	BV	REYNOLDS, James, Ed., Martindale: The Extra Pharmacopoeia. 31 st Edition, 1996. London, Royal Pharmaceutical Society. pp. 924-925, 1488-1489.	
	BW	SHARPE, et al, "Rapid regression of endometriosis by a new gonadotropin-releasing hormone antagonists in rats with surgically induced disease" Current Concepts in Endometriosis. 1990. 449-458.	
	BX	STOECKEMANN, et al, "Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats". Human Reproduction. 1995. 10(12):3264-3271.	
	BY	STRIETER, et al, "Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline", Biochemical and Biophysical Research Communications, September 30, 1988. 155(3):1230-1236.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.